Wednesday, 4 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Solara Active Pharma Sciences Business Update

Solara Active Pharma Sciences announced the successful closure of a US FDA inspection at its Puducherry Ibuprofen facility. The inspection, conducted in February 2026, concluded with a 'Voluntary Action Indicated' classification and issuance of an Establishment Inspection Report. The site remains in a state of cGMP compliance, supporting its global API manufacturing strategy.

Source

NSE filing, NSE: SOLARA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Solara Active Pharma Sciences Ltd: key numbers

Share price
₹629.75
Market cap
₹3,034 Cr
Revenue (annual)
₹1,369 Cr
Net profit (annual)
₹-7.41 Cr
P/E (TTM)
82.1×Sector 41.3×
Promoter holding
41.93%+0.00% QoQ
FII holding
10.71%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Solara Active Pharma Sciences Ltd

All →
13:37 IST NSE
Financial Results

Solara Active Pharma Sciences Q2 FY27 Results: Turns Profitable, Net Profit ₹28.5 Cr

Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.

Key figure
Net profit ₹28.5 Cr

Other business update announcements

All →